Publications

Spectrum and potency of ceftaroline against leading pathogens causing community acquired respiratory tract infections in Europe and South Africa, 2010, Lead author: Farrell DJ, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Antimicrobial activity of ceftaroline and comparator agents against contemporary (2010) Streptococcus pneumoniae from Europe and South Africa, Lead author: Farrell DJ, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Characterisation of resistance mechanisms and epidemiology of Enterobacteriaceae collected during a phase II clinical trial for ceftazidime avibactam, Lead author: Mendes RE, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Prevalence of ESBL and carbapenemase-producing phenotypes of Enterobacteriaceae identified in the 2010 AWARE surveillance programme, Lead author: Krause, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Occurrence and genetic analysis of OXA-48-producing strains in European countries, 2007-2010, Lead author: Castanheira M, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Activity of ceftaroline tested against methicillin-resistant Staphylococcus aureus clones from Australia and New Zealand, 2010, Lead author: Bell JM, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Antimicrobial activity of ceftaroline and comparator agents against contemporary (2010) Staphylococcus aureus isolates from Europe and South Africa, Lead author: Farrell DJ, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Oritavancin activity tested against Staphylococcus aureus responsible for documented infections in European hospitals, Lead author: Mendes RE, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Update on daptomycin activity and spectrum tested against Gram-positive organisms collected in 2011 from European medical centres, Lead author: Sader HS, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Activity of JNJ-Q2 against Staphylococcus aureus isolated from patients with acute bacterial skin and skin structure infection obtained during a phase II clinical trial, Lead author: Farrell DJ, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Adjusting EUCAST zone diameter breakpoints for Haemophilus influenzae on the Mueller-Hinton Fastidious media, Lead author: Ahman, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Contemporary doxycyline and tetracycline susceptibility testing using CLSI and EUCAST criteria for Gram-positive pathogens: results from SENTRY programme, Lead author: Jones RN, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Activity of moxifloxacin tested against 14,930 clinical isolates of Enterobacteriaceae from Europe, Lead author: Farrell DJ, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Optimizing echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations. by Lepak A, Castanheira M, Diekema D, Pfaller M and Andes D published in Antimicrob. Agents Chemother. 2012; 56 (11): 5875-5882

Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: Results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010). by Gales AC, Castanheira M, Jones RN and Sader HS published in Diagn. Microbiol. Infect. Dis. 2012; 73 (4): 354-360

Characterization of methicillin-resistant Staphylococcus aureus strains recovered from a phase IV clinical trial for linezolid versus vancomycin for the treatment of nosocomial pneumonia. by Mendes RE, Deshpande LM, Smyth DS, Shopsin B, Farrell DJ and Jones RN published in J. Clin. Microbiol. 2012; 50 (11): 3694-3702

ZAAPS program results for 2010: An activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries. by Flamm RK, Farrell DJ, Mendes RE, Ross JE, Sader HS and Jones RN published in J. Chemother. 2012; 24 (6): 328-337

Disk diffusion and MIC quality control ranges for BC-3205 and BC-3781, two novel pleuromutilin antibiotics. by Ross JE, Sader HS, Ivezic-Schoenfeld Z, Paukner S and Jones RN published in J. Clin. Microbiol. 2012; 50 (10): 3361-3364

In vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method. by He W, Kaniga K, Lynch AS, Flamm RK and Davies TA published in Diagn. Microbiol. Infect. Dis. 2012; 74 (4): 417-419

Molecular characterization of vancomycin-resistant Enterococcus spp. clinical isolates recovered from hospitalized patients among several medical institutions in China. by Sun H, Wang H, Xu Y, Jones RN, Costello AJ, Liu Y, Li G, Chen M and Mendes RE published in Diagn. Microbiol. Infect. Dis. 2012; 74 (4): 399-403

Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004-2008. by Pfaller MA, Neofytos D, Diekema D, Azie N, Meier-Kriesche HU, Quan SP and Horn D. published in Diagn. Microbiol. Infect. Dis. 2012; 74 (4): 323-331

Use of a surfactant (polysorbate 80) to improve MIC susceptibility testing results for polymyxin B and colistin. by Sader HS, Rhomberg PR, Flamm RK and Jones RN. published in Diagn. Microbiol. Infect. Dis. 2012; 74 (4): 412-414

Macrolide and tetracycline resistance among Moraxella catarrhalis isolates from 2009 to 2011. by Flamm RK, Sader HS, Farrell DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2012; 74 (2): 198-200

Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values. by Pfaller MA, Chaturvedi V, Diekema DJ, Ghannoum MA, Holliday NM, Killian SB, Knapp CC, Messer SA, Miskou A and Ramani R published in Diagn. Microbiol. Infect. Dis. 2012; 73 (4): 365-368

Candida glabrata: Multidrug resistance and increased virulence in a major opportunistic fungal pathogen. by Pfaller MA, Castanheira M, Lockhart SR and Jones RN published in Curr. Fungal Infect. Rep. 2012; 6 (3): 154-164

Advances in antifungal susceptibility testing of Candida, 2010-2012. by Pfaller MA, Castanheira M and Jones RN published in Curr. Fungal Infect. Rep. 2012; 6 (3): 141-153

Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. by Pfaller MA and Diekema DJ published in J. Clin. Microbiol. 2012; 50 (9): 2846-2856

Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance program. by Pfaller MA, Woosley LN, Messer SA, Jones RN and Castanheira M published in Mycopathologia 2012; 174 (4): 259-271

Activity of JNJ-Q2 against Staphylococcus aureus isolated from patients with acute bacterial skin and skin-structure infection obtained during a Phase 2 clinical trial. by Farrell DJ, Turner LL, Castanheira M and Jones RN published in Diagn. Microbiol. Infect. Dis. 2012; 74 (1): 73-74

Activity of JNJ-Q2, a novel fluoroquinolone, tested against Neisseria gonorrhoeae, including ciprofloxacin-resistant strains. by Biedenbach DJ, Turner LL, Jones RN and Farrell DJ published in Diagn. Microbiol. Infect. Dis. 2012; 74 (2): 204-206

Resistance trends in Gram-negative bacteria: Surveillance results from two Mexican hospitals, 2005-2010 by Morfin-Otero R, Tinoco-Favila JC, Sader HS, Salcido-Gutierrez L, Perez-Gomez HR, Gonzalez-Diaz E, Petersen L and Rodriguez-Noriega E published in BMC Res. Notes 2012; 5: 277

LEADER Surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers) by Flamm RK, Farrell DJ, Mendes RE, Ross JE, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2012; 4 (1): 54-61

Molecular epidemiology of Staphylococcus epidermidis clinical isolates from USA hospitals. by Mendes RE, Deshpande LM, Costello A and Farrell DJ published in Antimicrob. Agents Chemother. 2012; 56 (9): 4656-4661

Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: Results from CAPITAL Surveillance 2010. by Queenan AM, Pillar CM, Deane J, Sahm DF, Lynch AS, Flamm RK, Peterson J and Davies TA published in Diagn. Microbiol. Infect. Dis. 2012; 73 (3): 267-270

Transferable plasmid-mediated resistance to linezolid due to cfr in a human clinical isolate of Enterococcus faecalis by Diaz L, Kiratisin P, Mendes R, Panesso D, Singh KV and Arias CA published in Antimicrob. Agents Chemother. 2012; 56 (7): 3917-3922

The PATH (Prospective Antifungal Therapy) alliance registry and invasive fungal infections: Update 2012. by Azie N, Neofytos D, Pfaller M, Meier-Kriesche HU, Quan SP and Horn D published in Diagn. Microbiol. Infect. Dis. 2012; 73 (4): 293-300

Caspofungin Etest susceptibility testing of Candida species: Risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints. by Arendrup MC and Pfaller MA published in Antimicrob. Agents Chemother. 2012; 56 (7): 3965-3968

Ceftaroline applications for therapy in the United States by Corey GR and Jones RN published in Clin. Infect. Dis. 2012; 55 (Suppl 3): S171-S172

Ceftaroline potency among 9 US census regions: Report from the 2010 AWARE program. by Flamm RK, Sader HS, Farrell DJ and Jones RN published in Clin. Infect. Dis. 2012; 55 (Suppl 3): S194-S205

AWARE ceftaroline surveillance program (2008-2010); Trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. by Pfaller MA, Farrell DJ, Sader HS and Jones RN published in Clin. Infect Dis. 2012; 55 (Suppl 3): S187-S193

Antimicrobial activity of daptomycin in comparison to glycopeptides and other antimicrobials when tested against numerous species of coagulase-negative Staphylococcus. by Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2012; 73 (2): 212-214

Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. by Pfaller MA, Espinel-Ingroff A, Castanheira M, Cuenca-Estrella M, Diekema DJ, Fothergill A, Faller J, Ghannoum M, Jones RN, Lockhart SR, Ostrosky-Zeichner L and Pelaez T published in J. Clin. Microbiol. 2012; 50 (6): 2040-2046

Cryptococcus neoformans-Cryptococcus gattii species complex: An international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine. by Espinel-Ingroff A, Chowdhary A, Cuenca-Estrella M, Fothergill A, Fuller J, Hagen F, Govender N, Guarro J, Johnson E, Lass-Florl C, Lockhart SR, Martins MA, Meis JF, Melhem MS, Ostrosky-Zeichner L, and Turnidge J published in Antimicrob. Agents Chemother. 2012; 56 (6): 3107-3113

Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones. by Segreti J, Jones RN and Bertino JS published in J. Ocul. Pharmacol. Ther. 2012; 28 (1): 3-11

Summary of ceftaroline activity against pathogens in the United States, 2010: Report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program. by Flamm RK, Sader HS, Farrell DJ and Jones RN published in Antimicrob. Agents Chemother. 2012; 56 (6): 2933-2940

Antifungal drug resistance: Mechanisms, epidemiology, and consequences for treatment. by Pfaller MA published in Am. J. Med. 2012; 125 (1 Suppl): S3-S13

Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. by Fernandez J, Abbanat D, Shang W, He W, Amsler K, Hastings J, Queenan AM, Melton JL, Barron AM, Flamm RK and Lynch AS published in Antimicrob. Agents Chemother. 2012; 56 (3): 1476-1484

Expansion of clonal complex 258 KPC-2-producing Klebsiella pneumoniae in Latin American hospitals: Report of the SENTRY antimicrobial surveillance program. by Castanheira M, Costello AJ, Deshpande LM and Jones RN published in Antimicrob. Agents Chemother. 2012; 56 (3): 1668-1669

Evaluation of quinolone resistance-determining region mutations and efflux pump expression in Neisseria meningitidis resistant to fluoroquinolones. by Castanheira M, Deshpande LM, Jones RN and Farrell DJ published in Diagn. Microbiol. Infect. Dis. 2012; 72 (3): 263-266

Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods. by Castanheira M, Duncanson FP, Diekema DJ, Guarro J, Jones RN and Pfaller MA published in Antimicrob. Agents Chemother. 2012; 56 (1): 352-357